Chapter 11 3-Heteroarylquinuclidin-2-ene derivatives as muscarinic antagonists: Synthesis, structure-activity relationships and molecular modelling

Progress in Brain Research

Volumn 109, Issue C, 1996, Pages 141-145

  Nordvall, G ^a   Nilsson, B M ^a   Sundquist, S ^b   Johansson, G ^a   Glas, G ^b   Nilvebrant, L ^b   Hacksell, U ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b Department of Pharmacology ^*  (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; QUINUCLIDINE DERIVATIVE;

ANIMAL TISSUE; BRAIN CORTEX; CONFERENCE PAPER; DRUG SYNTHESIS; GUINEA PIG; HEART; MOLECULAR MODEL; NONHUMAN; PAROTID GLAND; PRIORITY JOURNAL; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION;

EID: 0030447045     PISSN: 00796123     EISSN: 18757855     Source Type: Book Series    
DOI: 10.1016/S0079-6123(08)62095-6     Document Type: Article

References (13)

1. Clemo, G.R., Hoggarth, E., 81. 5-Ethinylruban-5-ol and related compounds. J. Chem. Soc., 1941, 476-477.
2. Doad, G.J.S., Barltrop, J.A., Petty, C.M., Owen, T.C., A versatile and convenient synthesis of benzofurans. Tetrahedron Lett. 1 (1989), 1597-1598.
3. 3 receptors. J. Pharmacol. Exp. Ther. 1 (1987), 257-262.
4. Grimm, U., Moser, U., Mutschler, E., Lambrecht, G., Muscarinic receptors: focus on presynaptic mechanisms and recently developed novel agonists and antagonists. Pharmazie 1 (1994), 711-726.
5. Nilsson, B.M., Sundquist, S., Johansson, G., Nordvall, G., Glas, G., Nilvebrant, L., Hacksell, U., 3-Heteroaryl substituted quinuclidin-3-ol and quinuclidin-2-ene derivatives as muscarinic antagonists, synthesis and structureactivity relationships. J. Med. Chem. 1 (1995), 473-487.
6. Nilvebrant, L., Sparf, B., Muscarinic receptor binding in the parotid gland, different affinities of some anticholinergic drugs between the parotid gland and ileum. Scand. J. Gastroenterol. 17 (1982), 69-77 Suppl. 72.
7. Nilvebrant, L., Sparf, B., Muscarinic receptor binding in the guinea pig urinary bladder. Acta Pharmacol. Toxicol. 1 (1983), 30-38.
8. Nilvebrant, L., Sparf, B., Differences between binding affinities of some antimuscarinic drugs in the parotid gland and those in the urinary bladder and ileum. Acta Pharmacol. Toxicol. 1 (1983), 304-313.
9. Nilvebrant, L., Sparf, B., Dicyclomine, benzhexol and oxybutynin distinguish between sub-classes of muscarinic binding-sites. Eur. J. Pharmacol. 1 (1986), 133-143.
10. Nordvall, G., Hacksell, U., Binding-site modeling of the muscarinic ml receptor-a combination of homology-based and indirect approaches. J. Med. Chem. 1 (1993), 967-976.
11. Saunders, J., Cassidy, M., Freedman, S.B., Harley, E.A., Iversen, L.L., Kneen, C, MacLeod, A.M., Merchant, K.J., Snow, R.J., Baker, R., Novel quinuclidine-based ligands for the muscarinic cholinergic receptor. J. Med. Chem. 1 (1990), 1128-1138.
12. Verloop, A., The STERIMOL Approach to Drug Design., 1987, Decker, New York.
13. Wold, S., Johansson, E., Cocchi, M., PLS-partial least-squares projections to latent structures. Kubinyi, H., (eds.) 3D QSAR in Drug Design: Theory, Methods and Applications, 1993, ESCOM, Leiden, 523-550.